Dermatan sulfate (DS), also known as chondroitin sulfate (CS)-B, is a member of the linear polysaccharides called glycosaminoglycans (GAGs). The expression of CS/DS and DS proteoglycans is increased in several fibrotic renal diseases, including interstitial fibrosis, diabetic nephropathy, mesangial sclerosis and nephrosclerosis. Little, however, is known about structural alterations in DS in renal diseases. The aim of this study was to evaluate the renal expression of two different DS domains in renal transplant rejection and glomerular pathologies. DS expression was evaluated in normal renal tissue and in kidney biopsies obtained from patients with acute interstitial or vascular renal allograft rejection, patients with interstitial fibrosis and tubular atrophy (IF/TA), and from patients with focal segmental glomerulosclerosis (FSGS), membranous glomerulopathy (MGP) or systemic lupus erythematosus (SLE), using our unique specific anti-DS antibodies LKN1 and GD3A12. Expression of the 4/2,4-di-O-sulfated DS domain recognized by antibody LKN1 was decreased in the interstitium of transplant kidneys with IF/TA, which was accompanied by an increased expression of type I collagen, decorin and transforming growth factor beta (TGF-β), while its expression was increased in the interstitium in FSGS, MGP and SLE. Importantly, all patients showed glomerular LKN1 staining in contrast to the controls. Expression of the IdoA-Gal-NAc4SDS domain recognized by GD3A12 was similar in controls and patients. Our data suggest a role for the DS domain recognized by antibody LKN1 in renal diseases with early fibrosis. Further research is required to delineate the exact role of different DS domains in renal fibrosis.
Introduction
Dermatan sulfate (DS) is a member of the large family of linear polysaccharides called glycosaminoglycans (GAGs). DS is also known as chondroitin sulfate B (CS-B) and is composed of repeating disaccharide units consisting of N-acetyl galactosamine (GalNAc) and glucuronic acid (GlcA) residues. The presence of the epimerized form of GlcA, iduronic acid (IdoA), defines it as DS. Covalently bound to a core protein DS forms proteoglycans (PGs), such as decorin and biglycan [1, 2] . The level of complexity of DS is dictated by a variable structure and chain length of up to 40-100 disaccharide units. The uronic acid can be either a GlcA or IdoA with or without 2-O-sulfation, and the GalNAc residue can be 4-and/or 6-O-sulfated. These possibilities can result in the formation of several defined disaccharide units; CSA (4-Osulfated), CSB/DS (IdoA and 2,4-di-O-sulfated), CSC (6-O-sulfated), CSD (2,6-di-O-sulfated), CSE (4,6-di-O-sulfated) and CSEi (IdoA and 4,6-di-O-sulfated) [3] .
DS is able to bind a myriad of factors, including fibroblast growth factor (FGF)-1, -2 &-7, heparin cofactor II and interferon (IFN)-γ. Specific sulfation patterns and the amount of epimerization within a CS/DS chain dictate growth factor/cytokine binding and function, such as cell proliferation, signal transduction and extracellular matrix (ECM) modulation [2] . The biological roles of both the proteoglycan core protein and the DS side chains have been studied, mostly in relation to extracellular matrix components, especially collagens. These studies have indicated fundamental roles of the DSPGs biglycan and decorin in regulating collagen fibril formation in vivo [4, 5] , while the DS side chains have been implicated in influencing the mechanical strength of collagen fibrils in vitro as well [6] . The increase in extracellular matrix and collagen is related to fibrosis and sclerosis.
Glomerulosclerosis and tubulointerstitial fibrosis are common final pathological features of most end-stage kidney diseases irrespective of the underlying etiology [7] . It is also the final common pathway of renal allograft damage, where the specific features are interstitial fibrosis and tubular atrophy, which can lead to glomerulosclerosis resulting in a decline in glomerular filtration rate [8] . Renal allograft injury can roughly be divided as acute, mediated by cellular and/or antibody mediated rejection, or as chronic with moderate to severe interstitial fibrosis, tubular atrophy and absence of specific glomerular pathology in an early stage (IF/TA) [9] . Tubulointerstitial fibrosis involves inflammation, proliferation, apoptosis and fibrosis. An early identification of renal allograft loss could improve long-term allograft survival. Both acute and chronic rejection are associated with increased chemokine expression, many of which are GAG-binding [10] . There is an increase in circulating GAGs in patients with acute allograft rejection [11] and experimental heparin/synthetic sulfated oligosaccharides therapy has been shown to prolong transplant function and reduce rejection [12, 13] . It was shown that the heparan sulfate (HS) PG expression was increased in sclerotic glomeruli, while the CSPG expression was increased in the fibrotic interstitium in a renal transplant model in rats [10] . CS/DS and DSPGs have been reported to be increased in several fibrotic renal diseases, including interstitial fibrosis, diabetic nephropathy, mesangial sclerosis and nephrosclerosis [14, 15] . Changes in CS/DS content and modifications have been found in different animal models for renal disease [14, [16] [17] [18] . However, the precise role of DS in the ECM of both the normal and the fibrotic kidney is not well understood. Importantly, little is known about structural alterations in DS in renal diseases due to lack of proper tools for detection. In particular, specific antibodies directed against specific domains in DS could further facilitate research on the role of DS in renal fibrosis. Some antibodies recognizing both DS and CS have been described [19] , and previously we reported two specific anti-DS antibodies (GD3A12 and LKN1). The phage displayed-derived anti-DS antibody LKN1 was shown to be especially reactive with 4/2,4-di-Osulfated DS, whereas antibody GD3A12 recognized IdoA-Gal-NAc4S [20, 21] .
In the current study we elucidate the expression of the different DS domains defined by antibodies LKN1 and GD3A12 using a panel of renal biopsies obtained from patients with acute interstitial, acute vascular and chronic renal allograft rejections, and from patients with focal segmental glomerulosclerosis (FSGS), membranous glomerulopathy (MGP) and systemic lupus erythematosus (SLE). The expression of the DSPG decorin, type I collagen and transforming growth factor beta (TGF-β) was investigated as well. Our data revealed that the 4/2,4-di-O-sulfated DS domain recognized by antibody LKN1 was differentially expressed in patients, while expression of the IdoA-Gal-NAc4SDS domain recognized by GD3A12 was similar in controls and patients.
Materials and Methods

Human kidney specimens
This study was performed in accordance with the applicable rules concerning the review of the research ethics committee of the Radboud university medical center Nijmegen. We used archived renal biopsy material that was anonymized prior to us receiving these materials. Renal allograft biopsies were obtained from patients with (according to Banff '97 guidelines [22] ) acute interstitial (n = 6; Banff'97 class I, C4d negative), acute humoral/vascular (n = 6; Banff'97 class II, C4d positive) and chronic (n = 5; with slight to moderate fibrosis and tubular atrophy, class II) rejection, later called "Interstitial fibrosis and tubular atrophy (IF/TA), without evidence of any specific etiology" [23] . Note that these biopsies were previously obtained and scored according to the Banff '97 guidelines. Needle renal biopsies were obtained from patients with focal segmental glomerulosclerosis (FSGS, n = 11), membranous glomerulopathy (MGP, n = 6), systemic lupus erythematosus (SLE, n = 6). Four renal biopsies not showing any signs of rejection or other pathology were used as controls.
Immunofluorescence staining
Indirect immunofluorescence staining was performed on 2 μm cryostat renal sections. Sections were fixed in ice-cold acetone for 10 minutes and incubated with primary antibodies diluted in phosphate-buffered saline (PBS) containing 1% (w/v) bovine serum albumin (BSA, Sigma-Aldrich Chemie BV, Zwijndrecht, The Netherlands) and 0.05% sodium azide (IF-buffer) for 45 minutes at room temperature (RT). Primary antibodies included rabbit anti-bovine collagen type 1 (Millipore BV, Amsterdam, The Netherlands), mouse anti-human decorin (R&D Systems Europe Ltd. Oxon, United Kingdom), rabbit anti-transforming growth factor beta1 (TGF-β1) (Abcam, Cambridge, United Kingdom) and the VSV-tagged anti-DS antibodies LKN1 [20] and GD3A12 [21] . Sections were rinsed with PBS and incubated with anti-rabbit or anti-mouse Alexa 488-conjugated IgG (5 μg/ml, Molecular Probes, Leiden, The Netherlands) or anti-VSV-Cy3 (2 μg/ml, Sigma-Aldrich Chemie) in IF buffer for 45 minutes at RT. Sections were rinsed with PBS and subsequently fixed in 100% ethanol for 20 seconds, air-dried and embedded in Mowiol. The staining intensities of all antibodies were scored using arbitrary units (AU) on a scale between 0 and 4 (0 = no staining, 2 = intermediate staining and 4 = strong staining) by two investigators on blinded sections.
Statistical analysis
Data are presented as mean ± standard deviation (s.d.) and, if not normally distributed, as median with interquartile ranges. For comparisons of different groups Mann-Whitney U tests were used. Statistical analysis was performed using GraphPad Prism 5.0 (GraphPad Software Inc., San Diego, CA, USA).
Results
Decreased expression of the 4/2,4-di-O-sulfated DS domain defined by antibody LKN1 in the tubular interstitium in interstitial fibrosis and tubular atrophy (IF/TA)
The distribution of the 4/2,4-di-O-sulfated and IdoA-Gal-NAc4S DS domains recognized by, respectively, the LKN1 and GD3A12 antibody was analysed in biopsies with renal allograft rejection and controls (Figs 1 and 2 ). Relevant clinical data of the patients are given in Table 1 . In controls, the 4/2,4-di-O-sulfated DS domain defined by LKN1 was expressed in the tubular interstitium, including the matrix surrounding Bowman's capsule, with a distinct fibrillar expression pattern ( Fig 1A) . No expression inside the glomerulus was seen. Previously, we showed that this DS domain co-localized with type I collagen [20] .
In IF/TA, expression of the 4/2,4-di-O-sulfated DS domain recognized by antibody LKN1 was significantly decreased in the tubular interstitium (Fig 1D) , whereas the expression in the acute interstitial ( Fig 1B) and vascular renal allograft rejection ( Fig 1C) was similar to the control kidneys (Figs 1A and 2A). The strongly decreased expression of the 4/2,4-di-O-sulfated DS domain was accompanied by an increased expression of type I collagen, the DSPG decorin and TGF-β in IF/TA (Figs 1L, 1P, 1T and 2A). Type I collagen and decorin expression in acute interstitial (Fig 1J and 1N ) and acute vascular renal allograft rejection (Fig 1K and 1O ) was similar to the control kidneys (Fig 1I and 1M) . Furthermore, glomerular staining of LKN1 was increased in IF/TA. and a similar increase also occurred in acute interstitial and vascular rejection (Fig 2B) . Importantly, glomerular staining of TGF-β was also increased in acute interstitial and vascular rejection, and in IF/TA (Figs 1R-1T and 2B) compared to the control kidneys (Figs 1Q and 2B). The expression pattern of the IdoA-Gal-NAc4S DS domain recognized by the GD3A12 antibody in control kidney was similar to the expression pattern of the 4/2,4-di-O-sulfated DS domain defined by LKN1. Thus, also in this case no glomerular expression was observed ( Fig  1E) . Furthermore, no differences were observed between the expression of this IdoA-GalNAc4SDS domain in the control group (Fig 1E) , and in the groups of patients with acute interstitial (Fig 1F) , acute vascular renal allograft rejection (Fig 1G) or IF/TA (Figs 1H and 2A ).
Increased expression of the 4/2,4-di-O-sulfated DS domain defined by antibody LKN1 in the tubular interstitium and glomeruli in human glomerular diseases Since these 2 specific DS domains were differentially expressed in the different types of renal allograft rejection, we also analyzed their renal expression in three glomerular diseases FSGS, MGP and SLE. Relevant clinical data of these patients are given in Table 2 . In all these glomerular diseases, the 4/2,4-di-O-sulfated DS domain, recognized by the LKN1 antibody (Fig 3B-3D) , and type I collagen (Fig 3J-3L) were expressed in the glomerulus in contrast to the controls ( Figs 3A, 3I, and 4B) . Furthermore, expression of this DS domain was significantly increased in the tubular interstitium of patients with FSGS, MGP and SLE (Figs 3B-3D and 4A), which was accompanied by an increased expression of type I collagen as well (Figs 3J-3L and 4A). Expression of TGF-β was increased in the tubular interstitium of patients with FSGS and SLE ( Figs 3R, 3T, and 4A) . Importantly, the increased glomerular expression of the 4/ 
membranous glomerulopathy (MGP) (C, G, K, O, S) and systemic lupus erythematosus (SLE) (D, H, L, P, T) with the anti-DS antibodies LKN1 (A-D) and GD3A12 (E-H), anti-collagen type I (Coll I) (I-L), decorin (M-P) and transforming growth factor beta (TGF-β) (Q-T). Tubular interstitial and glomerular expression of the 4/2,4-di-O-sulfated DS domain defined by LKN1 and of type I collagen was increased in FSGS (B, J), MGP (C, K) and SLE (D, L) compared to control human kidney (A, I). Expression of the IdoA-Gal-NAc4S DS domain, recognized by GD3A12, and decorin was similar in the interstitium and glomeruli of patients (F-H, N-P) and controls (E, M). Glomerular expression of TGF-β was increased in FSGS (R), MGP (S) and SLE (T) compared to control (Q). Magnification A-P 100x, magnification Q-T 200x.
doi:10.1371/journal.pone.0134946.g003 
Interstitial fibrosis and tubular atrophy (0-3)
Values are given as median and range. Abbreviations: FSGS, focal segmental glomerulosclerosis; MGP, membranous glomerulopathy; SLE, systemic lupus erythematosus. Glomerulosclerosis, interstitial fibrosis and tubular atrophy were scored as absent (0), < 25% (1) GD3A12, and decorin were not expressed in the glomeruli of patients with glomerular diseases (Fig 3F-3H and 3N-3P) . Furthermore, the expression of the IdoA-Gal-NAc4S DS domain and decorin in the tubular compartment was similar in both normal and glomerular diseased kidneys (Figs 3E-3H, 3M-3P and 4A). In summary, we observed a differential expression of the 4/2,4-di-O-sulfated DS domain, recognized by antibody LKN1, in renal transplant rejection and glomerular pathologies. We analyzed the correlation between the expression of 4/2,4-di-O-sulfated DS domain recognized by antibody LKN1 and type I collagen in glomerular diseases, acute rejection and IF/TA, which may clarify the difference of LKN1 staining in the different renal diseases (Fig 5A) . We observed 3 patterns; 1) in acute allograft rejection expression of the 4/2,4-di-O-sulfated DS domain recognized by LKN1 is increased more than collagen type I; 2) in glomerular disease both expressions are increased; 3) but in IF/TA expression of the 4/2,4-di-O-sulfated DS domain is decreased, while collagen type I is increased. In contrast to the differential interstitial expression of the 4/2,4-di-O-sulfated DS domain recognized by antibody LKN1 among the various renal diseases, the expression of the IdoA-Gal-NAc4S DS domain recognized by GD3A12 is similar in healthy and diseased kidneys. Therefore, the expression ratio of 4/2,4-di-O-sulfated DS domain to IdoA-Gal-NAc4S DS domain might be useful in monitoring the progression of IF/TA (Fig 5B) . This information may be useful for diagnostic purposes on renal biopsies.
Discussion
This study shows the differential expression of the specific 4/2,4-di-O-sulfated and IdoA-GalNAc4S DS domains recognized by the anti-DS antibodies LKN1 and GD3A12, respectively, in normal kidney and in renal pathology. Previous studies showed the expression of DS (and CS) in the kidney, both in the glomerulus and in the tubular interstitium [14, 24, 25] . The 4/2,4-di-O-sulfated DS domain is expressed in the tubular interstitial space, but not in the healthy glomerulus, as is type I collagen [20] . Furthermore, the normal expression pattern of the 4/2,4-di-O-sulfated DS domain resembles the expression of the two DSPGs, decorin and biglycan, which are also expressed in the renal tubular interstitium with accumulations around the tubules, but no expression in the normal glomerulus [15, 26] . For the IdoA-Gal-NAc4S DS domain, the expression pattern in control rat kidney was previously shown in large blood vessels with a weaker staining present in the tubular interstitial space and near Bowman's capsule [21] . DS and DSPGs have been reported to be increased in several fibrotic renal diseases, including interstitial fibrosis, diabetic nephropathy, mesangial sclerosis and nephrosclerosis [14, 15] . In the unilateral urethral obstruction (UUO) model in the rat, a well established model of renal inflammation and fibrosis, fibrotic lesions showed ten-fold increase in CS/DS content and a decrease in the sulfation degree of CS/DS, accompanied by a lower IdoA content [14] .
The expression of the 4/2,4-di-O-sulfated DS domain recognized by LKN1 was significantly decreased in the tubular interstitium in biopsies of patients with IF/TA compared to biopsies of patients with acute rejection. In IF/TA there was an inverse correlation between the decreased expression of the 4/2,4-di-O-sulfated DS domain and the increased expression of decorin, TGF-β and type I collagen. Importantly, glomerular LKN1 staining was not observed in controls, while patients with different forms of renal allograft rejections did show a glomerular LKN1 staining. The increased glomerular expression of the 4/2,4-di-O-sulfated DS domain correlated with the increased glomerular expression of TGF-β in the biopsies with acute rejection and IF/TA, which corresponds to other studies [27, 28] . In biopsies of patients with glomerular disease, there was also an increased glomerular expression of the 4/2,4-di-O-sulfated Differential DS Expression in Renal Pathology DS domain, which was accompanied by glomerular expression of type I collagen and TGF-β. These data are in accordance to other studies that showed an upregulated expression of small leucine-rich proteoglycans and type I collagen in renal fibrosis, diabetic nephropathy and crescentic glomerulonephritis [29] [30] [31] . The expression of the 4/2,4-di-O-sulfated DS domain was significantly increased in the tubular interstitium of patients with glomerular disease, which was again accompanied by an increased expression of type I collagen, suggesting a role for this 4/2,4-di-O-sulfated DS domain in matrix remodelling and collagen formation in glomerular disease. In patients with FSGS and SLE, the increased expression of the 4/2,4-di-O-sulfated DS domain in the tubular interstitium, correlated with the increased expression of TGF-β, which was in accordance with the degree of interstitial fibrosis and tubular atrophy. This was also shown by other studies [32, 33] . Since the specific 4/2,4-di-O-sulfated DS domain is present at an earlier stage in the analyzed nephropathies, this anti-DS antibody might be useful in determining early changes in matrix deposition in the diseased kidney. It has been described that DS size increases in response to an insult, but returns to normal later on, thus regulating collagen fibril formation [34] . The increase in DS staining observed in the tubular interstitium using our anti-DS antibody LKN1 might reflect the changes in DS size and sulfation needed for initial matrix modelling. Type I collagen depositions were present in the analyzed glomerular diseases and there was a positive correlation with the expression of the DSPG decorin, TGF-β and the specific 4/2,4-di-O-sulfated DS domain recognized by LKN1, which indicates that the specific 4/2,4-di-O-sulfated DS domain plays different pathophysiological roles in renal allograft rejection and glomerular diseases. In IF/TA intima fibrosis/hyperplasia leads to arteriolopathy, which can induce ischemia. It is tempting to speculate that ischemia may induce a decreased expression of the specific 4/2,4-di-O-sulfated DS domain in contrast to the increased expression in glomerular diseases with less or no ischemia. Another study [35] showed that increased 6-O-sulfation of HS regulates the fibrotic response associated with chronic renal allograft failure. Interestingly, TGF-β induced up regulation of HS-6-O-endosulfatase-2 expression, which led to this changed sulfation pattern. In our study, the expression of the sulfotransferases dermatan 4-O-sulfotransferase 1 and /or the CS/DS-2-O-sulfotransferase may be changed in the glomeruli and tubular interstitium during the different stages of renal allograft rejection and glomerular diseases, causing differential expression of specific sulfated DS domains.
In contrast to the differential expression of the 4/2,4-di-O-sulfated DS domain in the control, the different types of renal allograft rejections and the glomerular diseases, the expression of the IdoA-Gal-NAc4S DS domain recognized by the anti-DS antibody GD3A12 was not different for either the tubular interstitium or the glomerulus. Therefore, these data indicate a dynamic role for the specific DS domains defined by the anti-DS antibody LKN1 in renal diseases. Moreover, it has been shown that GAGs are involved in chemokine sequestration in renal allograft rejection, allowing an inflammatory reaction to take place which can ultimately lead to transplant rejection [36] . An increase in CS expression was seen during acute renal allograft rejection and the biopsy specimens showed an enhanced capacity of binding a specific chemokine (CCL5). In a recent study using an experimental renal transplantation model an up regulation of the CSPG versican in kidneys with increased interstitial fibrosis was shown [10] .
In summary, we observed a differential expression of DS domains when comparing healthy kidneys and diseased kidneys. Our data suggest a role for the 4/2,4-di-O-sulfated DS domain recognized by antibody LKN1 in renal diseases with early fibrosis. However, further research is required to delineate the exact role of different DS domains in renal fibrosis. The described anti-DS antibodies might contribute to the future development of glycomimetics, which may ultimately lead to a better treatment of selected renal nephropathies and prevention of renal rejection.
